Patents by Inventor Wayne Drevets

Wayne Drevets has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240122928
    Abstract: The present invention relates to a method of treating agitation in a human patient with dementia, comprising administering to the human patient with dementia in need thereof a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof to treat agitation, wherein R1-R4 are defined herein: wherein the human patient has at least an about 20% reduction in their symptom of agitation, relative to the patient prior to administration of the compound of formula (I).
    Type: Application
    Filed: December 5, 2023
    Publication date: April 18, 2024
    Inventors: Wayne Drevets, Pascal Bonaventure, Gahan Pandina
  • Publication number: 20240000728
    Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 4, 2024
    Inventors: Wayne Drevets, Honglan Li, David Wood Hough, Jaskaran Singh, Ewa Wajs
  • Patent number: 11707440
    Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: July 25, 2023
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Wayne Drevets, Honglan Li, David Wood Hough, Jaskaran Singh, Ewa Wajs
  • Publication number: 20210386688
    Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 16, 2021
    Inventors: Carla Canuso, Wayne Drevets, Honglan Li, David Wood Hough, Adam Janik, Rachel Ochs-Ross, Jaskaran Singh, Ewa Wajs, Peter Zannikos
  • Publication number: 20190345245
    Abstract: A method for treating depression, anhedonia, or fatigue in a subject comprises administering an agent that blocks binding of IL-23 to IL-23 receptor, for example, an anti-IL-23 antibody or an antigen-binding fragment thereof that may comprise a heavy chain variable region and a light chain variable region of SEQ ID NO:106 and SEQ ID NO:116, respectively.
    Type: Application
    Filed: May 10, 2019
    Publication date: November 14, 2019
    Inventors: Wayne Drevets, Dai Wang, Gayle Wittenberg
  • Publication number: 20160338977
    Abstract: The present invention is directed to, inter alia, methods and kits for the treatment of depression (preferably, treatment resistant depression), or for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations) comprising administering esketamine according to certain dosing regimens.
    Type: Application
    Filed: May 19, 2016
    Publication date: November 24, 2016
    Applicant: Janssen Pharmaceutica NV
    Inventors: Jaskaran Singh, Ivo Caers, Ella Daly, Wayne Drevets
  • Publication number: 20060270698
    Abstract: Provided herein are methods and compositions for the treatment of depression and anxiety. The compositions comprise scopolamine, or an analog thereof, and can optionally include one or more psychoactive agents. Further provided is an inhaler comprising scopolamine, or an analog thereof, in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 25, 2005
    Publication date: November 30, 2006
    Inventors: Maura Furey, Wayne Drevets